Related Experiment Videos
Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas
Cancer Detection and Prevention
|January 1, 1983
Summary
Elevated urinary pseudouridine levels were found in lymphoma patients, particularly those with histiocytic lymphoma. However, pseudouridine excretion showed no correlation with disease stage or prognostic value in this study.
Area of Science:
- Biochemistry
- Oncology
- Urine Biomarkers
Background:
- Modified nucleosides, including pseudouridine, are excreted in increased amounts by patients with malignant lymphomas.
- Pseudouridine is a common modified nucleoside found in RNA.
Purpose of the Study:
- To determine the concentration of urinary pseudouridine in patients with malignant lymphomas.
- To investigate the correlation between pseudouridine excretion and lymphoma subtype, clinical stage, and prognostic relevance.
Main Methods:
- High-performance liquid chromatography (HPLC) was used to measure urinary pseudouridine concentrations.
- Urine samples from 48 patients with malignant lymphomas were analyzed.
- Patient data including lymphoma subtype, clinical stage, and survival outcomes were collected.
Main Results:
- Elevated pseudouridine excretion was observed in 50% of patients with histiocytic lymphoma, 33% with lymphocytic lymphoma, and 13% with Hodgkin's lymphoma.
- No correlation was found between pseudouridine excretion levels and the clinical stage of the disease.
- Initial pseudouridine excretion levels did not show prognostic value when comparing patients who deceased from lymphoma with those living disease-free.
Conclusions:
- Urinary pseudouridine levels vary among lymphoma subtypes but do not correlate with clinical stage.
- Pseudouridine excretion before treatment does not appear to be a significant prognostic marker for malignant lymphomas.